Clinical trials, including the SURPASS program, have shown that tirzepatide achieves greater reductions in body weight (up to 22.5%) and HbA1c levels compared to GLP-1 monotherapy with semaglutide [22, 23]
Moreover, previous studies have confirmed that SIRT5 expression is decreased in various kidney diseases, such as cisplatin induced acute kidney injury, clear cell renal cell carcinoma, and sepsis-induced acute kidney injury 29,30,31
Both tirzepatide and semaglutide can reduce the effectiveness of oral contraceptives
However, clinicians should conduct a thorough baseline assessment before initiating semaglutide
Enhanced oxidative stress markers and antioxidant imbalance in HIV infection and AIDS patients
Shannon Chatham, DO, a board-certified family medicine physician and medical director at Wisp